Pharma: Page 2

Acceleron shelves drug after disappointing readout

Despite hitting the main goal of a mid-stage neuromuscular study, Acceleron isn't convinced its drug offers meaningful improvement to muscle function or quality of life.​

By Jacob Bell • March 10, 2020

Tracking biopharma's response to the new coronavirus

The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.

By Jacob Bell • UPDATED: March 26, 2020 at noon

As US coronavirus cases mount, top drugmakers tell employees to work from home

Eli Lilly and Takeda are asking thousands of their U.S.-based employees to practice "social distancing," while Biogen tries to contain an outbreak among staff who attended a Boston meeting earlier this month.

By Ned Pagliarulo • March 09, 2020

AstraZeneca immunotherapy combination falls short in bladder cancer trial

Results from a Phase 3 bladder cancer study combining two checkpoint inhibitors failed to show a survival benefit, raising questions about other trials.

By Jonathan Gardner • March 06, 2020

Takeda starts work on treatment for coronavirus illness

The plan is to take blood proteins of patients recovering from the novel virus and turn them into an immune-boosting therapy that mitigates or prevents illness in others.

By Jacob Bell • March 04, 2020

Federal prosecutors make another claim against Mallinckrodt over Acthar prices

A quirk in the FDA approval for the multi-use drug allowed first Questcor and then Mallinckrodt to understate rebates owed to Medicaid, the lawsuit claims.

By Jonathan Gardner • March 04, 2020

High prices fuel pharma profits. New research provides more context

Drugmakers often enjoy significantly wider net income margins than large companies in other industries, and those profits have come amid steady list — and net — price hikes for hundreds of medicines.

By Ned Pagliarulo • March 03, 2020

New estimate puts cost to develop a new drug at $1B, adding to long-running debate

Pharma companies spend $300 million to $400 million bringing a new medicine to market, but per-product R&D costs are much higher after accounting for the many drugs that fail in testing.

By Jonathan Gardner • March 03, 2020

Sanofi wins US approval for myeloma drug key to its cancer ambitions

Sarclisa is the first cancer drug wholly owned by Sanofi to win an FDA OK in a decade — a milestone in the pharma's bid to play a larger role in oncology.

By Ned Pagliarulo • March 02, 2020

Sangamo sees vindication in Biogen gene-editing deal

Delivering products nearly ready for clinical testing has sparked greater dealmaking interest from big pharma, Sangamo's CEO told BioPharma Dive.

By Jonathan Gardner • Feb. 28, 2020

Takeda's small celiac disease bet turns into acquisition

Phase 1 data triggered a takeout of PvP Biologics worth up to $330 million, giving Takeda access to a drug invented by a University of Washington team.

By Jonathan Gardner • Feb. 26, 2020

Amid coronavirus fears, a generics giant pledges price stability

For the roughly two dozen drugs Sandoz deemed essential, it will refrain from list price increases, rebate decreases or other actions that would increase commercial drug costs for healthcare systems.

By Jacob Bell • Feb. 26, 2020

Mallinckrodt offers $1.6B in deal to settle opioid claims

Under the proposed settlement, which has the support of state governments, Mallinckrodt's generics unit would file for bankruptcy protection.

By Jonathan Gardner • Feb. 25, 2020

As shortages draw spotlight, Sanofi to spin out drug ingredient business

The new company will launch with significant size, employing 3,100 and drawing from a network of six factories across Europe.

By Ned Pagliarulo • Feb. 24, 2020

Chinese biotech enlists GSK in coronavirus vaccine effort

Clover Biopharmaceuticals will pair GSK's adjuvant technology with a protein-based vaccine it recently began developing in response to the viral outbreak.

By Ned Pagliarulo • Feb. 24, 2020

Esperion adds more competition to cholesterol drug market

Following an FDA approval Friday, Esperion intends to sell bempedoic acid under the brand name Nexletol for a price of about $10 per day.

By Jacob Bell • Feb. 21, 2020

Teva's neuroscience drug falls short at the finish line

Austedo, a main growth driver for Teva, failed two late-stage studies that were supposed to get the drug approved as a treatment for tics in young patients with Tourette's.

By Jacob Bell • Feb. 20, 2020

Sanofi starts work on coronavirus vaccine, bringing scale to global research effort

The French drugmaker joins J&J as the second large pharmaceutical company to begin development of a vaccine against the virus that's spread quickly across China.

By Ned Pagliarulo • Feb. 18, 2020

Coronavirus weighs on AstraZeneca's China expansion

The British drugmaker cautioned the disease outbreak could impact its sales in the country, where restrictions on travel and commerce have been imposed to contain the virus' spread.

By Jonathan Gardner • Feb. 14, 2020

Bristol-Myers finds FDA receptive to speedy review of key cell therapy

The regulator agreed to decide by mid-August on approval of Bristol-Myers' CAR-T treatment liso-cel​, one of three drugs prominently featured in the pharma's buyout of Celgene last year.

By Ned Pagliarulo • Feb. 13, 2020

J&J bolsters coronavirus vaccine work with BARDA partnership

Notably, J&J said it would work to "upscale" its production and manufacturing capacity for any vaccine that might result from its research efforts.

By Ned Pagliarulo • Feb. 12, 2020

Merck builds case for Keytruda use in breast cancer

When added to chemo, Merck's immunotherapy kept a difficult-to-treat form of breast cancer from progressing, provided patients had an important biomarker.

By Jonathan Gardner • Feb. 12, 2020

Sanofi shrinks executive team as new CEO reshapes French drugmaker

Four members of Sanofi's top leadership will depart, including current chief medical and digital officer Ameet Nathwani.

By Ned Pagliarulo • Feb. 12, 2020

Bayer, looking to grow pharmaceutical sales, seeds new research center

The German drugmaker is transferring a "large part" of its small molecule research unit in Berlin to contract developer and manufacturer Nuvisan, with the aim of building a new facility on Bayer's R&D campus.

By Jacob Bell • Feb. 11, 2020

In Alzheimer's, a plan to treat patients earlier doesn't work out for Lilly, Roche

Results from the DIAN-TU study chip away at the amyloid hypothesis' foundation, just as Biogen prepares to file its drug aducanumab for approval.

By Jonathan Gardner • Feb. 10, 2020